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a b s t r a c t
The infection routes of HIV-1 can affect several viral properties, including dissemination, pathogenesis,
and immune evasion. In this study, we evaluated the inhibitory activity of a wide variety of anti-HIV
drugs, focusing on the impact that different infection pathways have on their efﬁcacy. Compared to cell-
free infection, inhibitory activities were reduced in cell-to-cell productive transmission for all drugs
tested. We detected weak reporter-expressing target cells after cell-to-cell transmission in the presence
of integrase strand transfer inhibitors (INSTIs). Further analysis revealed that this expression was mainly
due to unintegrated circular HIV (cHIV) DNAs, consisting of 1-LTR and 2-LTR circles. When in vitro-
constructed cHIV DNAs were introduced into cells, the production of infectious and intercellular
transmittable virions was observed, suggesting that cHIV DNA could be a source of infectious virus.
These results highlight some advantages of the cell-to-cell infection mode for viral expansion,
particularly in the presence of anti-retroviral drugs.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Human immunodeﬁciency virus type 1 (HIV-1) infection causes
acquired immunodeﬁciency syndrome (AIDS) through gradual loss of
CD4þ T cells in infected individuals. To date, many potent anti-HIV
drugs have been developed and widely administered to patients to
sustain viral load suppression. These anti-HIV drugs target several
enzymes that are essential for HIV replication, including reverse
transcriptase (targeted by nucleoside/nucleotide reverse transcriptase
inhibitors [NRTIs] and non-nucleoside reverse transcriptase inhibitors
[NNRTIs]), integrase (targeted by integrase strand transfer inhibitors
[INSTIs]), and protease (targeted by protease inhibitors), as well as
critical steps in HIV infection such as interactions between the viral
envelope protein gp120 and chemokine receptors during viral entry,
and between another viral envelope protein, gp41, and the membrane
of target cells during fusion (De Clercq, 2002; Gandhi and Gandhi,
2014). Combination antiretroviral therapy (cART) consisting of these
drugs beneﬁts patients by preventing the onset of AIDS (Smith et al.,
2014).
HIV infects target cells mainly by two pathways: cell-free and cell-
to-cell infection (Gupta et al., 1989; Mothes et al., 2010). In cell-free
infection, infectious viral particles present in the extracellular milieu
infect CD4þ T cells via diffusion-limited spread. In cell-to-cell infec-
tion, on the other hand, HIV-1 is conveyed more directly from infected
to uninfected cells, where virions are captured in narrow intercellular
clefts and the physical connection formed between donor and target
cells, known as the virological synapse, actively contributes to the
efﬁcient viral expansion (Dale et al., 2013; Sattentau, 2008; Zhong
et al., 2013b). Moreover, events in the process of cell-to-cell HIV
infection are chronologically speciﬁed, i.e., HIV viral transfer, an early
event observed immediately after formation of cell-to-cell contact, is
followed by a later, sometimes independent, event, HIV productive
transmission, which ensures the infection (Puigdomenech et al., 2009).
Although the contribution of these events to viral infection is not fully
understood, it has been reported that some antiviral drugs preferen-
tially inhibit cell-free HIV-1 infection compared to cell-to-cell infec-
tion, suggesting that HIV-1 can efﬁciently expand by cell-to-cell
transmission even under active concentrations of inhibitors (Agosto
et al., 2014; Permanyer et al., 2012; Sigal et al., 2011). These observa-
tions highlight the importance of HIV-1 infection pathways for
understanding the mechanisms of viral pathogenesis, expansion,
persistence, and escape from anti-HIV pressure.
In this study, we evaluated the potency of several classes of anti-
HIV drugs targeting adsorption, entry, fusion, reverse transcription,
and integration, for three separate infection processes, i.e., cell-free
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infection, cell-to-cell viral transfer, and cell-to-cell productive trans-
mission/infection. By using a combination of blue ﬂuorescent protein
(BFP)-coding reporter HIV-1 and multicolor ﬂow cytometric analysis,
we quantiﬁed reporter expression in target cells under different
infection pathways (cell-free and cell-to-cell infection). We observed
varying degrees of inhibitory activity of anti-HIV drugs depending on
the infection route, the importance of which was especially apparent
for NRTIs. On the other hand, cell-to-cell HIV-1 viral transfer, quanti-
ﬁed by Gag staining in target cells at early phases, was only affected by
anti-HIV-1 drugs that target steps before reverse transcription. Impor-
tantly, suppressive activity of an anti-HIV compound was dependent
on viral burden (multiplicity of infection, MOI) in both cell-to-cell viral
transfer and productive transmission.
Notably, although INSTIs at higher doses completely blocked
cell-free infection, a certain level of target cells weakly expressing
BFP remained under cell-to-cell transmission conditions. These
cells showed reduced proviral number but an increase in unin-
tegrated circular HIV (cHIV) DNAs (1-long terminal repeat (LTR)
and 2-LTR DNAs), a hallmark of abortive integration (Sloan and
Wainberg, 2011), indicating that reporter expression arose from
extrachromosomal cHIV DNA. Although unintegrated cHIV DNA is
thought to be a non-productive substrate in viral replication (Sloan
and Wainberg, 2011), surprisingly, infectious HIV-1 was produced
by cells transfected with in vitro constructed cHIV DNAs. These
results suggest that unintegrated cHIV DNAs can contribute to viral
replication in some speciﬁc situations.
Even under continuous cART, HIV eradication cannot yet be
achieved because of the presence of long-lived reservoirs (Chun
et al., 2015; Donahue and Wainberg, 2013; Pierson et al., 2000), that
can produce HIV-1 virions after activation (Bruner et al., 2015).
Additionally, several factors such as ongoing viral replication and/or
sanctuary sites are proposed to support life-long infection, though
their impact is still not fully clear. Although the clinical relevance of
our observations has not been clariﬁed, unintegrated cHIV DNAs could
be a new factor for HIV-1 maintenance or replication.
Results
An approach to quantitatively analyze anti-HIV drug activity on
speciﬁc infection pathways
To precisely deﬁne the activity of anti-HIV drugs at different steps
of infection under infection mode-speciﬁc conditions, we devised an
evaluation system in which a combination of BFP-encoding HIV-1 and
multicolor ﬂow cytometric measurements enabled an accurate and
efﬁcient analysis of viral infection. In cell-free infection, recombinant
HIV-1NL-BFP and target MT-4 cells were separately treated with each
anti-HIV drug, and then the cells were infected (Fig. 1A). For the
evaluation of cell-to-cell HIV infection, a T cell-to-T cell co-culture
model was employed in which Jurkat and MT-4 cells were used as
donor and target cells, respectively (Fig. 1B). To prepare donor cells
uniformly infected with HIV-1, the pNL-BFP molecular clone was
introduced into Jurkat cells and they were cultured overnight to
induce the expression of HIV-1 genes. The cells were then co-cultured
with target MT-4 cells that were pre-labeled with a cell tracking
ﬂuorescent dye. After 6 h of co-culture, Gagþ target cells were
detected but BFP expression was not yet observed in the same
population, indicating that cell-to-cell viral transfer had occurred,
but productive transmission had not. After 30 h of co-culture, in
contrast, BFP expression in target cells was detected, indicating that
cell-to-cell productive transmission had been established in the
target cells.
Next, to evaluate whether cell-free infection could have occurred
by virions produced from donor cells during cell-to-cell co-culture
experiments, Gagþ or BFPþ target cells were quantiﬁed under
conditions of direct or separate culture with Transwell. In cell-to-cell
HIV-1 transfer, Gag staining in target cells was mostly the result of the
cell-to-cell routes, and the contribution of cell-free Gag transfer was
minimal ( 0.5%) (Supplementary Fig. S1A–C). Similarly, in cell-to-cell
productive infection experiments, HIV-1 was exclusively (99%)
transmitted by the cell-to-cell route (Supplementary Fig. S1D–F).
Inhibitory activity of anti-HIV agents on speciﬁc infection pathways
The inhibitory activity of a wide variety of anti-HIV drugs on
each infection pathway was measured using the system described
above. Within an effective drug concentration range, dextran
sulfate (DS5000), an adsorption inhibitor, decreased both cell-
free infection and cell-to-cell productive transmission with dose-
dependency, though the cell-free infection was more efﬁciently
suppressed (concentration that blocks viral infection by 90% [90%
effective concentration: EC90] of 88 nM) compared to cell-to-cell
transmission (EC90 of 635 nM) (Fig. 2A). Similar results were
observed for drugs targeting initial steps of viral infection; entry/
fusion inhibitors. CXCR4-targeting entry inhibitors FC131 (Fig. 2B)
and its parental peptide TF14016 (Fig. 2C) showed 2.4- and 3.8-fold
more effectiveness on cell-free infection, respectively. A ﬁrst-in-
class HIV-1 fusion inhibitor enfuvirtide (T-20) (Fig. 2D) and two
experimental next-generation fusion inhibitors SC34 (Fig. 2E) and
SC34EK (Fig. 2F) had 3.5-, 7.1-, and 5.6-fold increased efﬁcacy on
cell-free infection, respectively. Moreover, all NRTIs tested here
also presented similar antiviral proﬁles, in which cell-free infec-
tion was preferential target of inhibition (Fig. 2G–K). One NRTI,
azidothymidine (AZT), showed a more marked reduction in its
ability to inhibit cell-to-cell transmission (compared to cell-free
infection) with more than 125-fold change. Decreased inhibitory
activity in cell-to-cell compared to cell-free infection was also
observed for two NNRTIs, efavirenz (EFV) (Fig. 2L) and nevirapine
(NVP) (Fig. 2M), which showed 7.0- and 5.9-fold changes,
respectively.
Next, to compare the inhibitory efﬁcacy between the two types
of HIV-1 infection pathways more accurately, we determined the
instantaneous inhibitory potential (IIP) of each drug. IIP, deﬁned by
the EC50 values and the slope determined by a dose–response
inhibitory curve, can provide precise information about the inhi-
bitory potency of drugs (Sampah et al., 2011; Shen et al., 2008). To
directly compare the differences among classes of inhibitory drugs,
the fold change of IIPs between cell-to-cell and cell-free infection
conditions was calculated for each drug at its highest concentra-
tion tested. Among inhibitors, DS5000 and T-20 showed larger
change in IIP between cell-to-cell productive transmission and
cell-free infection (0.59- and 0.51-fold, respectively), while major
changes in IIP were observed for all the NRTIs tested (AZT,
tenofovir disoproxil fumarate [TDF], lamivudine [3TC], didanosine
[ddI], and abacavir [ABC]), ranging from 0.45- to 0.59-fold
(Fig. 2N), indicating that the anti-HIV-1 activity of the NRTIs was
relatively more affected by the pathway of HIV-1 infection.
We quantiﬁed BFPþ donor cells in cell-to-cell transmission
experiments, yet the values showed minimal changes over the
concentrations tested here (Fig. 2A–M). These results indicate that
HIV-1 infection was already established in the donor cells when
performing the assays. It should also be noted that the concentra-
tions of drugs used here did not affect cell viability; hence changes
in BFP expression used for the calculation of infectivity reﬂect a
bona ﬁde inhibitory activity of these drugs to HIV-1 transmission/
infection. Taken together, our results show that all anti-HIV-1
drugs tested here, but especially the NRTIs, had weaker inhibitory
activities during cell-to-cell productive transmission than during
cell-free infection.
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Inhibitory effects of antiretroviral agents on cell-to-cell HIV-1 viral
transfer
As a consequence of an initial event, HIV-1 particles are physically
delivered from infected to uninfected cells without replication, in a
process speciﬁcally recognized, such as cell-to-cell viral transfer or
physical pass of viral materials, distinct from replication-dependent
productive transmission (Puigdomenech et al., 2009). Although the
contribution of cell-to-cell viral transfer on productive infection is a
controversial issue, this viral transfer was suggested to be the
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Fig. 1. Experimental schema for the evaluation of the activity of antivirals on cell-free and cell-to-cell infection. (A) For cell-free infection, target MT-4 cells were infected
with cell-free HIV-1NL-BFP. BFP-expressing cells were quantiﬁed by ﬂow cytometric analysis after 48 h of culture. Bottom panels show mock-infected cells. (B) For cell-to-cell
infection, donor Jurkat cells were transfected with the pNL-BFP molecular clone. After an overnight culture, donor cells were co-cultured with eFluor670-labeled target MT-4
cells at a ratio of 1:1. Half of the mixed cells in a well were collected 6 h post-co-culture to quantify HIV-1 viral transfer by measuring Gagþ cells with anti-Gag antibody. The
remaining cells were cultured for another 24 h, and then HIV-1 productive transmission/infection was quantiﬁed by the measurement of BFPþ cells. Bottom panels show co-
culture experiments with mock-transfected cells.
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consequence of receptor-mediated endocytosis, which may be fol-
lowed by fusion between viral envelope proteins and the endosomal
membrane, resulting in productive infection (Puigdomenech et al.,
2009). To address the action of antiretrovirals on cell-to-cell viral
transfer, Gagþ target MT-4 cells, co-cultured with HIV-1-loaded donor
Jurkat cells, were quantiﬁed 6 h post-co-culture by intracellular
staining with anti-Gag antibody as previously reported (Kuhl et al.,
2010). As mentioned above, cell-to-cell viral transfer occurred but
cell-to-cell infection (detected as BFP expression) was not observed at
this time point. Thus, cell-to-cell viral transfer could be evaluated
independently from productive transmission using this system. All
drugs tested here caused minimal changes in Gag and BFP expression
in donor cells (Fig. 3A–M), indicating that the expression of HIV-1
genes was not restricted to early genes such as nef, which should be
expressed together with BFP through the IRES, but was also observed
in late genes such as gag at this time point; thus the donor cells in this
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Fig. 2. Activity of anti-HIV-1 drugs against cell-free infection and cell-to-cell infection. The anti-HIV-1 activity of inhibitors targeting adsorption (A, DS5000), entry (B, FC131;
C, TF14016), fusion (D, T-20; E, SC34; F, SC34EK), and reverse transcription (G, AZT; H, TDF; I, 3TC; J, ddI; K, ABC; L, EFV; M, NVP) was evaluated for cell-free infection (blue)
and cell-to-cell productive HIV-1 infection (red). Data shown are means and standard deviations of the ratio of target cells that are BFPþ to no drug control, obtained from at
least three experiments. BFP expression in donor cells for cell-to-cell infection is also displayed (gray). Asterisks indicate statistical signiﬁcance of the difference in %BFPþ
cells between cell-free and cell-to-cell infection at each drug concentration: nPo0.05; nnPo0.01; nnnPo0.001 (determined by the F-distribution and Student's t-test).
(N) Fold change of mean values of IIP between cell-to-cell and cell-free HIV-1 infection conditions for each drug at the highest dose was calculated and is displayed by class of
anti-HIV drug.
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assay system were suitable as such. We found that Gag transfer to
target cells was suppressed with dose-dependency by inhibitors
targeting adsorption (Fig. 3A), entry (Fig. 3B and C) and fusion
(Fig. 3D–F), which block the HIV-1 life cycle prior to reverse
transcription. At the highest doses tested in this study, 0.46- to 0.64-
fold reduced Gagþ target cells compared to Gagþ donor cells were
observed when using these inhibitors (Fig. 3N). On the other hand, all
NRTIs (Fig. 3G–K) and NNRTIs (Fig. 3L–M) tested caused minimal
changes in Gag transfer (Fig. 3N: 0.84- to 1.03-fold). These results
suggest that HIV-1 transfer relies on the interactions of gp120 with
CD4 and co-receptor, and subsequent membrane fusion.
Multiplicity of infection is the factor that can affect the suppressive
effects of drugs on cell-to-cell infection
Previous studies reported that the inhibitory potential of
antiviral agents and neutralizing antibodies against cell-to-cell
HIV-1 infection was affected by MOI (Abela et al., 2012; Agosto
et al., 2014; Duncan et al., 2013; Titanji et al., 2013). Hence, we also
evaluated the inﬂuence of MOI on the suppressive activity of
TF14016, which could inhibit both cell-to-cell productive trans-
mission (Fig. 2C) and viral transfer (Fig. 3C) with high potency. We
modiﬁed the MOI by changing the ratio of donor (HIV-loaded
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Fig. 3. Effect of anti-HIV drugs on cell-to-cell HIV-1 viral transfer. Cell-to-cell HIV-1 viral transfer was evaluated at 6 h post-co-culture by quantiﬁcation of Gag in target cells.
Data shown are means and standard deviations of Gagþ donor cells (blue), Gagþ target cells (red), and BFPþ donor cells (gray) (% of no drug control), obtained from at least
three experiments, in the presence of adsorption (A, DS5000), entry (B, FC131; C, TF14016), fusion (D, T-20; E, SC34; F, SC34EK), and reverse transcription (G, AZT; H, TDF; I,
3TC; J, ddI; K, ABC; L, EFV; M, NVP) inhibitors. Asterisks indicate the statistical signiﬁcance of differences in %Gagþ cells between donor and target populations at each drug
concentration: nPo0.05; nnPo0.01; nnnPo0.001 (determined by Student's t-test). (N) Fold change of % Gag-expressing cells between donor and target cells for each drug
at the highest dose was calculated and is displayed by class of anti-HIV drug.
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Jurkat cells) to target (MT-4 cells), on both cell-to-cell events.
Moderate (donor to target ratio of 5:1) and high (donor to target
ratio of 20:1) MOIs showed decreased activity of TF14016 on cell-
to-cell productive infection (Fig. 4A) and viral transfer (Fig. 4B) in a
MOI-dependent manner, compared to low (donor to target ratio of
1:1, condition that was used in our evaluation shown in Figs. 2 and
3) MOI, indicating that increasing cell-to-cell HIV-1 transmission
and Gag transfer may result from a higher number of donor cells,
constituting a barrier for efﬁcient suppression by antiviral drugs.
Inhibitory activity of INSTIs on cell-free and cell-to-cell HIV-1
infection
Next, we evaluated the inhibitory activity of INSTIs, the latest class
of anti-HIV drugs to be approved, on cell-free and cell-to-cell infection
pathways. All three INSTIs, raltegravir (RAL), elvitegravir (EVG), and
dolutegravir (DTG), showed substantial suppression of cell-free infec-
tion within higher dose ranges (Fig. 5A–C). However, in cell-to-cell
productive transmission, the percentage of INSTI-treated cells that
were BFPþ remained higher than that of cells treated with other
classes of HIV inhibitors (compare Fig. 2A–M and Fig. 5A–C). With RAL
treatment, only 7.1–9.9% inhibitory activity (compared to cell-free
infection) was achieved in a range of 100 nM–10 μM (Fig. 5A).
Similarly, the cell-to-cell infection inhibitory activities of EVG and
DTG, with a range of 10 nM–1 μM, were only 7.6–8.1% and 8.6–8.9%
respectively of their activities on cell-free infection (Fig. 5B and C).
However, cell-to-cell viral transfer, measured by Gag expression in
target cells, was not affected by any INSTIs (Fig. 5D–F). To directly
measure the anti-HIV activity of INSTIs, target cells were labeled with
CFSE and infected with cell-free HIV-1 or by co-culture with HIV-1-
loaded Jurkat cells in the presence of the drugs. After 48 h of cell-free
infection or 30 h of co-culture infection, target cells were ﬁxed and
sorted based on the CFSE staining, subsequently quantifying inte-
grated HIV-1 by qPCR. Target cells were highly puriﬁed (contamina-
tion of CFSE-negative donor cells were less than 1.5%). Compared to
cell-free infection, increased integrated HIV-1 DNA was observed in
cell-to-cell transmission at the corresponding concentrations (3.0-fold
for 10 μM RAL [Fig. 5G], 5.7-fold for 1 μM EVG [Fig. 5H], and 2.5-fold
for 1 μM DTG [Fig. 5I]). These results showed a discrepancy between
HIV-1 infection levels evaluated by BFP expression and integrated
DNA levels in target cells under cell-to-cell transmission in the
presence of INSTIs.
To clarify the mechanism underlying the considerable percentage
of BFP-expressing target cells that remain under productive transmis-
sionwhen treating with INSTIs, we focused on unintegrated HIV DNA.
It is well known that unintegrated HIV DNA is preferentially produced
by INSTIs treatment. HIV-1 gene expression from unintegrated HIV
DNA has been reported to occur (Brussel and Sonigo, 2004), but its
intensity was weak compared to that from the integrated provirus
(Van Loock et al., 2013). Therefore we calculated the mean ﬂuores-
cence intensity (MFI) of BFP in BFP-expressing target cells. Although
inhibitors other than INSTIs changed BFP MFI slightly (Fig. 6A–F),
higher concentrations of INSTIs suppressed BFP MFI more signiﬁ-
cantly, to about half the normal level (Fig. 6G–I), suggesting that the
weak BFP expression in target cells treated with INSTIs was derived
from unintegrated cHIV DNA.
To directly elucidate the role of cHIV in BFP expression and clarify
the inhibitory potency of INSTIs against integration in cell-to-cell
productive transmission, levels of HIV-1 DNA products were mea-
sured. After a 30-h co-culture period in the presence of 1 μM EVG or
DTG as shown in Fig. 1B, cells were sorted based on the expression of
BFP and CFSE staining to discriminate between donor and target cells.
The following populations were sorting-puriﬁed: BFP/CFSE (HIV-
negative donor Jurkat cells), BFP/CFSEþ (HIV-negative target MT-4
cells), BFPþ/CFSE- (HIV-positive donor Jurkat cells), and BFPþ/CFSEþ
(HIV-positive target MT-4 cells) (Supplementary Fig. S2). EVG treat-
ment resulted in a signiﬁcant increase in copy number of unintegrated
cHIV DNAs (1-LTR DNA [Fig. 6J] and 2-LTR DNA [Fig. 6K]) in the BFPþ
target population (6.0- and 30-fold increases, respectively, compared
to the no drug control). In contrast, integrated HIV-1 DNA was
decreased 25-fold in the same population (Fig. 6L). Similar results
were observed for another INSTI, DTG, in a different batch of
experiments. DTG increased 1-LTR (3.7-fold) (Fig. 6M) and 2-LTR
(13-fold) (Fig. 6N) DNA products, but decreased integrated DNA (13-
fold) (Fig. 6O) in the BFPþ target population. These results indicate
that in productive cell-to-cell transmission, although INSTIs certainly
blocked the integration of HIV-1, non-integrating byproducts 1-LTR
and 2-LTR DNAs, increased concomitantly and then BFP was weakly
expressed from them.
Production of infectious and cell-to-cell transmittable HIV-1 from
circularized HIV-1 DNA-transfected cells
As a bona ﬁde INSTI function, EVG and DTG decreased the
integration of HIV-1NL-BFP into the genome of target MT-4 cells under
productive cell-to-cell infection conditions, while increasing the
number of unintegrated cHIV DNAs. To examine the role of these
cHIV DNAs in the viral life cycle, we introduced in vitro-constructed
circularized HIV DNA into cells (Fig. 7A). To construct cHIV DNAs
identical to those naturally produced in the infected cells, we ﬁrst
made plasmids that contained gag-split HIV-1NL-BFP by SphI digestion
(originally there is one site in the gag gene) with internal one-LTR or
two-LTR containing junctions, named pBS-1LTRNLBFP and pBS-
2LTRNLBFP, respectively (Fig. 7B). Then the HIV-1 genome was isolated
from these plasmids using SphI digestion at both termini of the
genome, resulting in a linear form of HIV-1 DNAwith an internal LTR,
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named l1LTRNL-BFP and l2LTRNL-BFP. Finally, the obtained linear DNA
form was circularized by intramolecular self-ligation using T4 DNA
ligase, and named c1LTRNLBFP and c2LTRNLBFP.
As shown in Fig. 7A, each form of HIV-1 DNA was transfected into
293FT cells and the supernatant was recovered after 72 h. The
remaining transfected cells were co-cultured with target MT-4 cells
for an additional period of 30 h, as in the cell-to-cell transmission
assay, and then BFP expressionwas quantiﬁed and DNAwas extracted.
Initially, the levels of 1-LTR and 2-LTR DNAs were quantiﬁed by qPCR
using DNA extracted from the co-cultured cells, including both DNA-
transfected 293FT and target MT-4 cells. The level of 1-LTR DNA was
more than 150 fold higher in cells transfected with each 1-LTR and 2-
LTR forms. Note that the 1-LTR form cannot be accurately quantiﬁed
by qPCR because primers that amplify 1-LTR can also amplify 2-LTR,
but not vice versa (Kelly et al., 2008; Sloan and Wainberg, 2011),
indicating that the increase of 1-LTR product in each form of 2-LTR-
transfected cell was due to unspeciﬁc ampliﬁcation of 2-LTR. However,
the level of 2-LTR DNA in cells transfected with each form of 2-LTR
was more than 500-fold higher than that in pNL-BFP-transfected cells,
while cells transfected with each form of 1-LTR presented a level that
was almost similar to that of pNL-BFP (Fig. 7C). Supernatant collected
from the pNL-BFP-transfected cell culture that was used as a positive
control, contained 260729 ng mL1 of p24 antigen (Fig. 7D). In
contrast, although as expected, very small and almost unmeasurable
amounts of p24 production was observed in cells transfected with
linear or plasmid DNA forms, with values below 4 ng mL1 and
10 pgmL1, respectively. On the other hand, transfection with the
circular form yielded p24 production of 93.177.8 and
49.975.6 ngmL1 for c1LTRNLBFP and c2LTRNLBFP, respectively. A
similar trend was observed in the production levels of infectious
HIV-1NL-BFP. When transfecting with pNL-BFP, 27104 units mL1 of
infectious HIV-1 were produced as quantiﬁed by the MAGI assay
(Fig. 7E). Although little HIV-1 production was observed from the
plasmid and linear forms (0.5–0.7% of pNL-BFP), a substantial amount
was evidently produced from the circular forms (48% by c1LTRNLBFP
and 23% by c2LTRNLBFP). These results were further conﬁrmed by
infection-induced BFP expression using CEM cells. As expected, BFP
expression in CEM cells induced by supernatants recovered from the
plasmid DNA form- and the linear DNA form-transfected cell cultures,
was similar to background levels, while c1LTRNLBFP and c2LTRNLBFP
induced 57 and 29% BFP expression compared to that of pNL-BFP,
respectively (Fig. 7F). The production levels of p24 and infectious
virions from the circular 1-LTR form was higher than the ones from
the 2-LTR form, which is consistent with a previous report showing
higher viral protein expression was from the 1-LTR form (Cara et al.,
1996). These results indicate that cHIV DNAs can act as a source of
progeny virions.
BFP expressionwas detected in CFSE-labeled target MT-4 cells that
had been co-cultured for 30 h with pNL-BFP-transfected 293FT cells
(Fig. 7B). However, no BFP expression was detected in the target cells
co-cultured with mock- or plasmid form of HIV-1 DNA-transfected
cells. Only a small number of MT-4 cells were BFPþ after co-culture
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with the linear form-transfected cells, probably because some linear
HIV DNA concatemerized during the transfection process. In addition,
BFP expression was observed in the MT-4 cells co-cultured with
circular forms of 1-LTR- or 2-LTR-transfected cells. These results
indicate that cHIV DNA led to the production of virions infective not
only under cell-free infection conditions but also under the cell-to-
cell route.
Discussion
It has been reported that cell-to-cell HIV infection has kinetic merit
for spreading the virus more efﬁciently than cell-free infection
(Dimitrov et al., 1993; Sato et al., 1992). Moreover, the cell-to-cell
pathway is thought to be advantageous for immune evasion (Chen
et al., 2007; Durham et al., 2012). These observations highlight the
importance of virus infection pathways in viral pathogenesis, expansion,
and persistence, particularly in the presence of antiretroviral drugs. In
the ﬁrst part of this study, we compared the anti-HIV-1 activity of
diverse classes of antiviral agents, including those targeting adsorption,
entry, fusion, reverse transcription, and integration. We observed a
varying degree of weakened inhibitory activity for cell-to-cell HIV-1
productive transmission compared to cell-free infection in all tested
inhibitors within effective concentration ranges, as judged by dose-
infection curves and EC90 values. When comparing IIP values, which
accurately reﬂect the inhibitory potency of the drugs, a clear difference
was observed in the activities of NRTIs under these two infection
pathways.
Several groups have reported the contribution of HIV-1 infection
pathways on the susceptibility to anti-HIV drugs (Agosto et al., 2014;
Duncan et al., 2013; Gupta et al., 1989; Mathez et al., 1993; Permanyer
et al., 2012; Sigal et al., 2011), and our results were consistent with a
previous report by Agosto et al. (2014) in which AZT and TDF showed
reduced activity in cell-to-cell infection. Similar studies of infection
pathway-dependent differences in antiretroviral drug activity have
also been done with other viruses. We reported previously that AZT
and TDF showed preferential inhibitory activity against simian retro-
virus type 4, a simian type D retrovirus that naturally infects cyn-
omolgus monkeys, under cell-free infection conditions, but weakened
activity in cell-to-cell infection (Togami et al., 2013). A similar
observation was reported regarding another simian-tropic virus,
simian immunodeﬁciency virus (Deng et al., 2012). These reports
highlight the fact that infection pathway-dependent differences in
anti-retroviral drug potency are based more on the properties of the
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drug than on the retrovirus/lentivirus species. At the molecular level,
NRTIs require phosphorylation to reach their active forms (Piliero,
2004), but the phosphorylation efﬁcacy varies among cell types, e.g.,
AZT is efﬁciently phosphorylated by cellular enzymes mostly in
activated cells (Gao et al., 1993). These features of NRTIs should affect
their effectiveness based on the evaluation using different cell sources
(cell lines or primary CD4þ T cells), and in addition, it is possible that
saturation of inhibitors and/or exhaustion of intracellular active
inhibitors by the more massive virus inﬂux associated with cell-to-
cell productive transmission, may explain the lower efﬁcacy of NRTIs
in cell-to-cell infection.
It has long been believed that during HIV-1 infection, virions
fuse to the plasma membrane of target cells. However, observa-
tions that suggest the contribution of endocytic entry of HIV-1 is
accumulating; i.e., contact-dependent receptor-mediated endocy-
tic entry of HIV-1, referred to as cell-to-cell viral transfer
(Puigdomenech et al., 2009), has been proposed to play an
important role (Miyauchi et al., 2009; Permanyer et al., 2010),
although contribution of this pathway on productive HIV-1 infec-
tion is still under debate. In this study, we carefully clariﬁed which
steps are required for cell-to-cell viral transfer by using anti-HIV
drugs targeting each step of infection. At higher doses within the
effective concentration range, drugs targeting steps prior to
reverse transcription, such as adsorption, entry, and fusion, were
found to block Gag transfer, suggesting that interactions of the
viral envelope proteins with CD4 and CXCR4, and the fusion step
are essential for cell-to-cell X4-tropic HIV-1 transfer. However,
although CD4-gp120 interaction has been demonstrated to be
essential for cell-to-cell viral transfer, the contributions of co-
receptor interaction and fusion appear different among reports
(Blanco et al., 2004; Chen et al., 2007; Emerson et al., 2010; Groot
et al., 2008; Martin et al., 2010; Massanella et al., 2009), and hence
are still under investigation. It has been proposed that internaliza-
tion of CXCR4 triggered by binding its endogenous ligand SDF-1/
CXCL12 is an additional anti-HIV mechanism (Altenburg et al.,
2010; Amara et al., 1997). We also reported the down-regulation of
CXCR4 expression induced by CXCR4 antagonists and HIV-1 gp120
through macropinocytosis (Masuda et al., 2012; Tanaka et al.,
2012), proposing an additional HIV-1 entry pathway using the
cellular machinery. Internalization of CXCR4 by its antagonists was
reported to be lower compared to that induced by its endogenous
ligand (Masuda et al., 2012), which correlates with the incomplete
inhibition of Gag transfer by FC131 and TF14016 in our assays.
These observations suggest that gp120-induced CXCR4-mediated
macropinocytosis partly contributes to HIV-1 transfer in our
assays, as well as in other scenarios such as drug accessibility to
the virological synapse (Martin et al., 2010).
It has been known that HIV-1 early genes such as nef and rev
are expressed from extrachromosomal cHIV DNA (Gillim-Ross
et al., 2005; Sloan and Wainberg, 2011), and their expression is
low compared to those originating from the integrated provirus
(Wu and Marsh, 2003). We demonstrated that the presence of
INSTIs during productive cell-to-cell infection experiments led to
target cells with weak BFP expression (theoretically with the same
level as nef) by causing the accumulation of unintegrated cHIV-1
DNAs (1-LTR and 2-LTR DNAs). It has been reported that transmis-
sion of a high number of HIV-1 copies from infected to uninfected
cells is one feature of cell-to-cell infection (Sigal et al., 2011), and
multiple integration events are observed under such conditions
(45). Our observations indicate that this multi-copy transmission
also contributes to an abnormal increase in cHIV-1 DNA caused by
failed integration in the presence of INSTIs.
In the second part of this study, we detected production of HIV-
1 from in vitro-constructed cHIV-1 DNAs that were identical to
those occurring in a natural HIV-1 infectious course. Previously,
other groups performed similar experiments; p24 production was
observed from cHIV DNA-transfected cells (Cara et al., 1996); SV40
origin of replication-introduced, integrase catalytic core domain-
mutated-HIV-1 was maintained episomally and was transcription-
ally active in SV40 large T antigen-expressing cells (Lu et al., 2004).
More recently, Trinité et al. reported de novo HIV-1 production
from unintegrated HIV-1 DNA in primary CD4þ T cells by
cytokine-activation after infection (Trinite et al., 2013). In the
current study, we clearly demonstrated that the produced virus
was infectious and intercellularly transmittable.
Several groups have described the persistence of the 2-LTR
form in vivo; and some groups reported that extrachromosomal
cHIV DNA was detected in infected patients without detectable
viral RNA (Cara et al., 2002; Sharkey et al., 2000). Moreover,
replication-competent HIV-1 can be isolated from infected
patients undergoing cART (Sahu et al., 2010), and the envelope
protein of HIV-1 re-emerging upon interruption of therapy was
genetically similar to the episomal cHIV DNA and not to the
integrated provirus (Sharkey et al., 2011). This indicates that
episomal cHIV DNA is present under successful cART, with the
presence of ongoing replication and de novo infection. On the
other hand, to gain a deeper insight into residual viremia, several
clinical studies were conducted with intensiﬁcation of cART by the
addition of other potent anti-HIV drugs, yet residual viremia was
not decreased (Dinoso et al., 2009; Gandhi et al., 2010, 2012).
Based on these results, residual viremia seems to arise from HIV-1-
infected reservoir cells, not from the consequence of ongoing viral
replication. At present, the contribution of ongoing replication to
persistent HIV-1 infection is not clear. These diverse observations
may reﬂect a complex situation consisting of the interplay
between multiple viral infection pathways, the immune response,
and the viral life cycle.
Although 2-LTR viral DNA was previously reported to be a
precursor of integratable infectious retrovirus (Panganiban and
Temin, 1984), this hypothesis is currently not accepted. However,
Thierry et al. recently provided new insight into the role of 2-LTRs
for the viral replication cycle; where accumulated 2-LTR forms by
RAL treatment in vitro could be converted to linear forms by RAL
withdrawal, which were then integrated (Thierry et al., 2015).
Although our observations that accumulation of cHIV DNAs by
INSTIs were especially emphasized under cell-to-cell transmission,
they suggest a cryptic role for unintegrated cHIV DNA in viral
replication.
Conclusions
In this study, we observed cell-to-cell infection pathway-
speciﬁc properties of anti-HIV drugs, such as the weakened
activity of NRTIs against cell-to-cell productive infection, and the
inhibition of cell-to-cell viral transfer by those drugs acting on
steps prior to reverse transcription. We also found that during cell-
to-cell productive infection in the presence of INSTIs, relatively
large amounts of unintegrated cHIV DNAs are found in target cells,
and that these cHIV DNAs are transcriptionally active at a low level
and can produce infectious virions. These ﬁndings highlight the
advantages of certain HIV-1 infection pathways for escaping drug
pressure, and also the potential relevance of viral spread from
unintegrated viral DNA.
Material and methods
Antiviral agents
DS5000, AZT, ddI, and 3TC were obtained from Sigma (St. Louis,
MO, USA). ABC, NVP, and EFV were obtained from Toronto
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Research Chemicals (North York, ON, Canada). TDF and RAL were
obtained through the AIDS Research and Reference Reagent
Program, National Institute of Allergy and Infectious Diseases
(NIAID), National Institutes of Health (NIH). The INSTIs, DTG and
EVG, and a different batch of RAL were obtained from Selleck
Chemicals (Houston, TX, USA). Two CXCR4 antagonists, FC131 and
TF14016, were synthesized as described previously (Fujii et al.,
2003; Tamamura et al., 2003). Three peptide fusion inhibitors,
T-20, SC34, and SC34EK, were synthesized based on previous
reports (Nishikawa et al., 2009; Otaka et al., 2002; Shimura
et al., 2010).
Cells and viruses
The human T-cell lines, Jurkat, CEM, and MT-4 were cultured in
RPMI 1640 medium supplemented with 10% fetal calf serum (FCS),
2 mM L-glutamine, 100 U mL1 of penicillin and 50 μg mL1 of
streptomycin. 293FT and HeLa-CD4/CCR5-LTR/β-galactosidase
cells were maintained as described previously (Shimura et al.,
2008; Togami et al., 2013).
The pNL4-3-based molecular clone containing the BFP-
encoding gene, pNL-BFP, was constructed by the substitution of
the GFP gene in pNLENG1-IRES (kindly provided by Dr. David N.
Levy, New York University College of Dentistry, NY, USA) with the
BFP gene of pTagBFP-N (Evrogen, Moscow, Russia) by an overlap
extension PCR method similar to the one described previously
(Imbeault et al., 2009) with primers as follows (sequence of BFP
gene underlined): Outer-F (NL4-3), 50-GAATTAGATAAATGGG-
CAAGTTTGTGG-30; Reverse (BFP_NL4-3), 50-CCTTAATCAGCTCGCT-
CATCTTATAGCAAAATCCTTTCCAAGCC-30; Forward (BFP_NL4-3), 50-
CTGGGGCACAAGCTTAATTAAGCCGCCACCATGGAGGGTT-30; Outer-
R (NL4-3), 50-GGCACAAGCAGCATTGTTAGC-30; BFP-F (BFP_NL4-3),
50-GGCTTGGAAAGGATTTTGCTATAAGATGAGCGAGCTGATTAAGG-
30; BFP-R (BFP_NL4-3), 50-AACCCTCCATGGTGGCGGCTTAATTAAG-
CTTGTGCCCCAG-30; Inner-F (NL4-3), 50-GCTGTACTTTCTATAGT-
GAATAGAGTTA-30; Inner-R (NL4-3), 50-TTGCTACTTGTGATTGCTC-
CATG-30. The plasmid was puriﬁed with the EndoFree Plasmid
Maxi Kit (Qiagen, Hilden, Germany), and recombinant HIV-1NL-BFP
was propagated by transfection into 293FT cells.
Evaluation of susceptibility to anti-HIV drugs
For cell-free infection experiments, HIV-1NL-BFP (20 ng of p24) and
target MT-4 cells (1.25105) were separately incubated in a CO2
incubator in the presence of the same concentrations of a drug. After
30 min of treatment, the virus and the cells were mixed, and then
cultured for 48 h. For cell-to-cell infection experiments, donor Jurkat
cells were transfected with pNL-BFP (2.5-5.0 μg per 106 cells) in
100 μL Neon tips using the Neon Transfection system (Invitrogen, Life
Technologies) at 1350 V, 10 ms, 3 pulses as the manufacturer
instructed. After an overnight culture, plasmid-loaded Jurkat cells
were washed and resuspended at 5105 cells mL1 in 10% FCS/
RPMI1640. To discriminate between donor and target cells, we labeled
target MT-4 cells with 2.5 μM Cell Proliferation Dye (CPD) eFluor 670
(eBioscience, San Diego, CA, USA) as the manufacturer instructed. After
extensive washing with cold 20% FCS/RPMI1640 and warm 10% FCS/
RPMI1640, labeled cells were resuspended at 5105 cells mL1 in
10% FCS/RPMI1640. Both donor and target cells were incubated
separately with the same concentrations of a drug for 30 min, and
then they were mixed and co-cultured. Six hours later, half of the
mixed cells were collected to evaluate cell-to-cell HIV-1 Gag transfer.
The remaining cells were cultured for further 24 h and then collected
for the analysis of cell-to-cell HIV-1 productive transmission. Antiviral
activities of inhibitors are presented as EC90 or IIP (Sampah et al., 2011;
Shen et al., 2008).
Flow cytometric analysis
Cells collected in the cell-free infection and cell-to-cell produc-
tive infection experiments were washed with PBS, ﬁxed using BD
CellFIX (BD Biosciences, San Jose, CA, USA) for 30 min at 4 1C,
washed with PBS again, and analyzed using a BD FACSVerse (BD
Biosciences). For the cell-to-cell HIV-1 Gag transfer assay, cells
were washed with PBS and treated with BD Cytoﬁx/Cytoperm
Fixation/Permeabilization solution (BD Biosciences) for 20 min at
4 1C. The cells were then washed with BD Perm/Wash Buffer (BD
Biosciences) and stained with anti-HIV-1 Gag antibody KC57-RD1
(Beckman Coulter, Brea, CA, USA) diluted with BD Perm/Wash
Buffer for 20 min at 4 1C. Stained cells were washed with BD Perm/
Wash Buffer and resuspended in PBS, then immediately analyzed
using a BD FACSVerse. The data obtained was analyzed with
FlowJo (TreeStar, Ashland, OR, USA).
Cell sorting
Cells were sorted as described previously with modiﬁcations
(Zhong et al., 2013a). Brieﬂy, cells were ﬁxed with 4% formaldehyde
in PBS overnight at 4 1C. Fixed cells were washed, resuspended in FACS
buffer (0.5% FCS and 2mM EDTA in PBS), and sorted using a BD
FACSAria II or IIIu (BD Biosicences). For cell sorting, target MT-4 cells
were pre-labeled with 5 μM 5-(and-6)-carboxyﬂuorescein diacetate,
succinimidyl ester (CFSE) (Molecular Probe, Life Technologies, Carls-
bad, CA, USA) as described previously (Quah and Parish, 2010), instead
of CPD eFluor 670.
DNA extraction and real-time PCR
DNA was extracted from cells using the DNeasy Blood & Tissue Kit
(Qiagen) as described previously (Zhong et al., 2013a). Real-time
quantitative PCR was performed using the THUNDERBIRD Probe qPCR
Mix (TOYOBO, Osaka, Japan) and the StepOnePlus Real-Time PCR
system (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) to
detect 1-LTR (Jacque and Stevenson, 2006; Sakurai et al., 2009) and 2-
LTR (Butler et al., 2001) DNAs with known copy number controls. For
normalization, β-actin ampliﬁcation was used (Carter et al., 2001).
Quantiﬁcation of integrated HIV DNA was performed by a two-step
ampliﬁcation as described (Agosto et al., 2007) with some modiﬁca-
tions. Brieﬂy, the ﬁrst ampliﬁcation was performed by TaKaRa LA Taq
Hot Start Version (Takara Bio, Otsu, Japan) with primers of genomic
Alu forward, 50-GCCTCCCAAACTGCTGGGATTACAG-30 and HIV gag
reverse, 50-GTTCCTGCTATGTCACTTCC-30 in a volume of 50 μL. PCR
conditions were 1 min at 94 1C and 20 cycles of 10 s at 98 1C, 30 s at
50 1C, and 2.5 min at 72 1C. The second ampliﬁcation was performed
by real-time PCR using 2 μL of ﬁrst PCR samples with primes of Alu-
F2, 50-TGGGAGCTCTCTGGCTAACT-30 and Alu-R2, 50-AACAGACGGGCA-
CACACTAC-30, and a probe of 50-FAM-AGCCTCAATAAAGCTTGCCTT-
GAGTGC-TAMRA-30. First PCR products performed without genomic
Alu forward primer (ampliﬁcation by HIV gag reverse primer only)
were used as ampliﬁcation control. Data were normalized by β-actin
and analyzed by the ΔΔCt method.
Construction of cHIV DNAs
DNA was extracted from HIV-1NL-BFP-infected MT-4 cells using
DNAzol Reagent (Invitrogen, Life Technologies). The 30-LTR-containing
sequence, encompassing the XhoI and NarI restriction enzyme recog-
nition sites at both ends, was ampliﬁed from the extracted DNA by Tks
Gﬂex DNA Polymerase (Takara Bio) with these primers: forward (50-
CAGTATCTCGAGACCTAGAAAAACATG-30; nucleotides 10189-10215 of
pNL-BFP) and reverse (50-GTTCGGGCGCCACTGCTAGAGATTTTC-30;
621-647). The ampliﬁed product (842 bp) was cloned into pCR-Blunt
II-TOPO (Invitrogen, life Technologies), and designated as pCR-1LTR.
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The two-LTR-containing sequence encompassed by XhoI and NarI sites
was constructed as follows: linear pCR-1LTR and a one-LTR fragment
to be inserted were each ampliﬁed from pCR-1LTR by PCR with two
sets of primers (forward primer, 50-CGAACAAGGGCGAATTCTGCAGA-
TATCCAT-30 and reverse primer, 50-ACTGCTAGAGATTTTCCACACTGAC-
TAAAA-30: ampliﬁed product, 4355 bp) and (forward primer, 50-
AAAATCTCTAGCAGTACTGGAAGGGCTAATTCAC-30 and reverse primer
50-ATTCGCCCTTGTTCGGGCGCCACTGCTAGAGAT-30: ampliﬁed product,
674 bp). Then both DNA products were puriﬁed and fused by using
the In-Fusion HD Cloning Kit (Takara Bio). The plasmid, designated as
pCR-2LTR, has tandem 30-LTR sequences with a junction of GTAC
between the LTR termini. Next, pNL-BFP and pCR-1LTR or pCR-2LTR
were digested with XhoI and NarI, and ligated by using T4 DNA ligase
(Takara Bio), in order to obtain intermediates. Ligated products were
puriﬁed and linearized by SphI digestion. This fragment was inserted
into the SphI site of pBluescript II SK (þ) (Agilent Technologies, Santa
Clara, CA, USA), which had been modiﬁed by introducing the site into
its multiple-cloning site. These plasmids were sequence-conﬁrmed
and designated as pBS-1LTRNL-BFP and pBS-2LTRNL-BFP, respectively. To
construct DNA substrates mimicking extrachromosomal cHIV DNA,
pBS-1LTRNL-BFP or pBS-2LTRNL-BFP were re-cut with SphI and the
fragment was gel puriﬁed to eliminate the plasmid backbone. Recov-
ered DNA, composed of the HIV genome only, was self-ligated with T4
DNA ligase under diluted DNA concentration (below approximately
8 ng μL1) in the absence of monovalent ions to ensure an intramo-
lecular circularization based on previous reports (Dugaiczyk et al.,
1975; Hayashi et al., 1985). The remaining linear substrates or
concatemers, a byproduct potentially formed during the ligation
reaction, were hydrolyzed by Plasmid-Safe ATP-Dependent DNase
(Exonuclease V) (Epicentre, Illumina, Madison, WI, USA), and intact
circularized DNA was puriﬁed and resuspended in TE buffer.
Production of infectious HIV from circularized HIV
In vitro-constructed cHIV DNA was transfected into 293FT cells
using Lipofectamine 2000 (Invitrogen, Life Technologies). The
supernatant was recovered 3 days post-transfection to check the
production of the virus by HIV-1 p24 Antigen ELISA (ZeptoMetrix,
Bufallo, NY, USA) and infectivity by MAGI assay and BFP expression
in CEM cells. The remaining cells were co-cultured with CFSE-
labeled MT-4 cells for 30 h. Mixed cells were then divided into two
groups: ﬂow cytometric analysis for BFP expression and DNA
extraction for real-time PCR as mentioned above.
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